Register
Community
Overview
Experts
Editors
Fellows
Code of conduct
AI Guidelines for Physicians
Company
About Us
FAQs
Privacy Policy
Terms of Use
Careers
Programs
News
News Releases
Press Coverage
Publications
Blog
Contact Us
Sign in
Please select the option that best describes you:
Topics:
Rheumatology
•
Inflammatory eye disorders
•
Pediatric Rheumatology
What is your recommended rheumatic disease evaluation for a pediatric patient presenting with interstitial keratitis and a negative infectious disease workup (e.g., HSV, syphilis, Lyme)?
Related Questions
How would you approach the management of dry corneal melt in a patient requiring high dose systemic steroids and no apparent underlying systemic autoimmune disease?
Should the age at which patients transition from pediatric to adult care differ depending on the disease diagnosis?
Do you continue biologics in sJIA patients who develop lung disease on anti IL-1 or anti IL-6 therapies?
Do you recommend genetic screening for FMF in asymptomatic first-degree relatives with a strong family history (multiple family members, severe/refractory disease)?
Is there a benefit to having a transition period in which a patient continues following with their previous pediatric rheumatologist while establishing care with a new adult rheumatologist?
What are some of the biggest challenges you run into when patients transition from pediatric to adult care?
Would you consider combination belimumab and anakinra for a patient who has SLE and MAS?
How do you discuss sexual health with pediatric patients transitioning to adult rheumatology care when the patient is accompanied by parents or caregiver?
In patients with possible early SLE or undifferentiated disease can multiomics be used to help predict what disease phenotype they will develop?
What is your approach to screening patients with sJIA for associated lung disease?
